Maxim Group Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $120
Viking Therapeutics Options Spot-On: On October 25th, 90,685 Contracts Were Traded, With 218.76K Open Interest
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $95 to $125
"Weight loss drug newcomer" Viking (VKTX.US) Q3 performance exceeds expectations, VK2735 prospects are unanimously bullish on Wall Street.
viking therapeutics surged on Thursday, as Wall Street has high hopes for its obesity candidate drug VK2735 latest developments, and the company also announced better-than-expected financial data for the third quarter.
Why Viking Therapeutics Stock Soared by Nearly 21% on Thursday
Market Climbs Following Tesla Earnings Beat | Wall Street Today
Viking Therapeutics Options Spot-On: On October 24th, 105.23K Contracts Were Traded, With 200.08K Open Interest
Viking Therapeutics Shares Rise 20.70% Following Q3 Results
Sector Update: Health Care Stocks Decline Thursday Afternoon
3 Health Care Stocks Moving In Thursday's Intraday Session
Q3 2024 Viking Therapeutics Inc Earnings Call
Viking Therapeutics Jumps as Obesity Updates Outshine Q3 Beat
UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday
Health and Wellness Industry Embraces Surge in Demand for Weight Loss Drugs
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $90 to $138
Express News | Viking Therapeutics Inc : Raymond James Raises Target Price to $122 From $118
3 Growth Stocks That Have Generated 1,000% Returns Since the Last Presidential Election (and They've All Outperformed Nvidia)
Express News | Market-Moving News for October 24th
Viking Therapeutics: Strong Financial Position and Promising Pipeline Justify Buy Rating
Earnings Call: Viking Therapeutics Q3 Financials and Clinical Updates